Polynucleotide injections are injectable treatments derived from purified DNA fragments that work by stimulating tissue repair and supporting the skin’s natural regenerative processes. Clinical evidence suggests improvements in skin quality, hydration, and elasticity, though research is still maturing. Suitability depends on individual skin assessment rather than trend alone.

Polynucleotide injections: what the current evidence actually shows and the questions to ask before trying a trending treatment

Scroll through any aesthetics forum or beauty editorial right now and you will encounter polynucleotide injections described as everything from a subtle skin-quality treatment to a near-miraculous regenerative solution. The reality, as is almost always the case with trending injectables, sits somewhere more measured and more interesting than the marketing suggests. If you are researching this treatment seriously, what you actually need is a clear account of the mechanism, an honest reading of the current evidence, and a practical framework for deciding whether it belongs in your personalised protocol.

This article goes deeper than the broad overview of regenerative aesthetics covered in the evidence-based guide to collagen-stimulating treatments. Here, the focus is specifically on polynucleotides: what they are, what the science currently supports, where the gaps remain, and the questions worth asking before you commit to a course of treatment.

—

What are polynucleotides and how do they actually work in the skin?

Polynucleotides are long-chain DNA fragments. In the context of injectable aesthetics, they are derived from biological sources, purified, and prepared in a form that can be introduced into the skin to interact with living tissue. The mechanism is not simply about adding volume or blocking a muscle. It is fundamentally about signalling, specifically, encouraging the skin’s own repair and regenerative processes to become more active.

Once injected into the dermis, polynucleotides interact with receptors on fibroblasts, the cells responsible for producing collagen, elastin, and hyaluronic acid. Research suggests this interaction encourages fibroblast proliferation and activity, which in turn supports the structural components of skin that decline with age, UV exposure, and environmental stress. Polynucleotides also appear to have antioxidant properties and may support local tissue hydration by influencing the extracellular matrix.

The result, when it occurs, is not an immediate visible change. It is a gradual improvement in skin quality, texture, and resilience as the tissue responds over weeks and months. This places polynucleotides firmly in the regenerative category rather than the volumising or muscle-relaxing categories.

Where do polynucleotides come from and how are they prepared for injection?

Most polynucleotide preparations used in aesthetic medicine are derived from salmon or trout sperm DNA. This is not incidental. Fish DNA shares a high degree of structural similarity with human DNA, which makes it biologically compatible and reduces the likelihood of an immune response. The raw material undergoes extensive purification to remove proteins that could trigger allergic reactions, leaving behind the purified DNA fragments in a sterile, injectable form.

The preparation process matters because not all polynucleotide formulations are equivalent. Molecular weight, concentration, and the degree of purification all influence how a product behaves in tissue. This is one reason why clinical outcomes can vary across different formulations, even when the category label is the same.

What is the difference between polynucleotides and other skin quality injectables?

The distinction worth understanding is between treatments that add something to the skin and treatments that ask the skin to do something differently. Hyaluronic acid-based skin boosters (sometimes called bio-remodelling injectables) primarily improve hydration and stimulate some collagen production by introducing hyaluronic acid into the dermis. Polynucleotides do not add hyaluronic acid. They work almost entirely through biological signalling, encouraging the skin’s own cells to produce more of what they have already been making, just less efficiently.

This makes polynucleotides a genuinely different category of treatment, not simply a newer version of something familiar. Whether that difference translates into meaningfully different outcomes for your specific skin concerns depends on careful assessment rather than category preference.

—

What does the clinical evidence for polynucleotide injections actually show?

The evidence base for polynucleotide injections has grown considerably over the past decade, though it is still developing. Published studies, predominantly from South Korean, Italian, and Spanish research groups, generally report improvements in skin hydration, elasticity, and overall quality following a course of polynucleotide injections. Histological studies, which examine skin tissue directly, show increased fibroblast activity and collagen density in treated areas, which supports the proposed mechanism of action.

What the evidence does not yet provide in abundance is large-scale, long-term, randomised controlled trial data comparing polynucleotides directly against established alternatives across diverse populations. Much of the published research involves smaller sample sizes, shorter follow-up periods, and varying assessment methodologies. This does not mean the treatment is ineffective. It means the evidence is still maturing, and honest interpretation requires acknowledging that distinction.

Which skin concerns have the most clinical support for polynucleotide treatment?

The strongest clinical support currently exists for improvements in skin quality broadly defined: hydration, texture, fine lines related to skin laxity rather than volume loss, and overall radiance. Studies examining under-eye skin, where the tissue is thin and particularly prone to showing signs of fatigue and ageing, report encouraging outcomes with polynucleotide injections in this area.

There is also reasonable evidence supporting polynucleotide use in the context of skin that has been damaged by UV exposure, as well as in post-procedural recovery where tissue regeneration is a priority. Some clinicians use polynucleotides alongside treatments such as microneedling with Dermapen 4 or laser resurfacing, on the basis that the regenerative signalling may support healing and enhance the overall response.

What are the honest limitations of the current research?

Several limitations are worth naming clearly. First, many studies use self-reported patient satisfaction as a primary outcome measure, which is subjective and susceptible to placebo effect. Second, the variability in formulations across studies makes it difficult to draw conclusions that apply universally to all polynucleotide products. Third, most published studies follow participants for three to six months, which is not long enough to understand how durable the improvements are or whether repeated courses are necessary to maintain them.

You deserve to know that when a treatment is trending, the published evidence often lags behind the clinical enthusiasm. Polynucleotides are not an exception to this pattern.

—

How do you evaluate whether a trending injectable treatment is right for you?

The fact that a treatment is generating significant interest is neither a reason to pursue it nor a reason to dismiss it. The more useful question is whether the evidence supports its use for your specific concern, in your specific skin, at this point in your skin health journey.

This is where the difference between population-level evidence and individual suitability becomes practically important. A clinical study might demonstrate that a group of participants with mild to moderate skin laxity showed measurable improvements in elasticity after three sessions. That finding is meaningful, but it does not tell you whether your skin, with its particular history of sun exposure, hormonal changes, previous treatments, and current condition, will respond in the same way.

The difference between population-level evidence and individual suitability

Population-level evidence tells you what is possible and plausible. Individual suitability assessment tells you what is likely for you. The two are related but not the same. A treatment with strong population-level evidence may still be a poor choice for your skin if your primary concern is volume loss rather than quality, or if your skin’s barrier function needs to be addressed before any injectable treatment is appropriate.

Conversely, a treatment with a still-developing evidence base may be a reasonable choice for you if the mechanism aligns with your concern, your practitioner has relevant training and experience with the formulation, and you understand and accept the current limitations of the research.

Red flags to watch for when a new treatment is being heavily marketed

Heavy marketing of a new injectable treatment does not automatically indicate poor quality, but it does warrant additional scrutiny. Watch for clinics that cannot explain the mechanism of action clearly, that present the treatment as suitable for everyone, or that frame the evidence as more settled than it is. Be cautious if you are offered a treatment at a first appointment without a detailed skin assessment, if the practitioner cannot answer your questions about realistic timelines and expected improvement, or if the conversation focuses on the treatment rather than your skin.

A diagnostic-first approach means that the assessment leads to the treatment recommendation, not the other way around. If you feel that the treatment recommendation preceded any genuine evaluation of your skin, that is worth noting.

—

The questions you should ask before agreeing to polynucleotide injections

Deciding to proceed with any injectable treatment deserves more than a brief conversation. The questions below are not designed to make the process adversarial. They are designed to give you the information you need to make a genuinely informed decision, and to help you assess whether the practitioner in front of you is approaching your care with the rigour it deserves.

Questions about your practitioner’s training and assessment process

Ask directly about the practitioner’s formal training in polynucleotide injections, not just general injectable experience. Ask whether they use any diagnostic tools to assess your skin before recommending treatment. A VISIA skin analysis, for example, can reveal subsurface changes in pigmentation, texture, and UV damage that are not visible to the naked eye, and this kind of objective data should inform treatment decisions.

Ask how the practitioner determines the appropriate injection depth, volume, and technique for your skin specifically. Polynucleotides are typically injected into the superficial to mid-dermis, but the precise approach varies depending on the treatment area and the formulation being used. Ask whether they have treated concerns similar to yours before and what outcomes they have observed. Ask what happens if you experience an adverse reaction, and whether the practice has protocols and equipment in place for managing complications.

Questions about realistic outcomes, timelines, and what happens if results are not what you hoped

Ask how many sessions are typically needed before any improvement becomes visible. Most polynucleotide protocols involve an initial course of two to four sessions spaced two to four weeks apart, followed by maintenance sessions at longer intervals. Visible improvement generally begins to emerge after the second or third session, with more noticeable changes at three to six months as collagen remodelling progresses.

Ask what realistic improvement looks like for your specific concern, and ask the practitioner to be precise rather than general. “Improved skin quality” is not a specific enough answer. Ask whether there is any photographic documentation process so that you can compare your skin before and after the course objectively.

Ask what happens if you complete the initial course and do not see the improvement you were hoping for. Is there a reassessment process? Would a different approach be considered? A practitioner who is confident in their assessment process will be comfortable answering this question directly.

—

How polynucleotide injections fit within a broader, assessment-led skin health approach

Polynucleotide injections are not a standalone solution for every skin concern, and they are rarely the only element of a well-constructed skin health protocol. Understanding where they fit, and where they do not, requires thinking about your skin’s current condition, your primary concerns, and the range of tools available.

For skin that is showing early signs of quality decline, fine lines related to dehydration and reduced elasticity, or dullness associated with slower cellular turnover, polynucleotides may be a well-matched first-line regenerative option. The treatment asks relatively little of the skin in terms of recovery and works gradually in alignment with the skin’s own biology.

When polynucleotides may complement other treatments and when they may be sufficient alone

Polynucleotides are often used alongside other treatments rather than instead of them. If your primary concern is skin quality and you have no significant volume loss or deep structural changes, a course of polynucleotide injections may be sufficient on its own to produce a meaningful improvement. If your concerns include volume loss, deeper folds, or significant laxity, polynucleotides are more likely to be one component of a broader protocol that might include hyaluronic acid-based dermal fillers, bio-remodelling injectables, or energy-based treatments.

The combination of polynucleotide injections with microneedling using Dermapen 4 is an area of growing clinical interest, with some practitioners reporting that the regenerative signalling from polynucleotides may enhance the skin’s response to the controlled micro-injury of microneedling. This is not yet supported by large-scale controlled trial data, but the theoretical rationale is coherent and the combination is being used in practice with careful patient selection.

What polynucleotides are unlikely to address adequately on their own: significant volume deficit, pronounced skin laxity requiring structural support, pigmentation concerns, or vascular changes. These concerns require different treatment categories, and a careful assessment will identify which concerns are present before any treatment is recommended.

What a diagnostic-first consultation for polynucleotide treatment looks like in practice

A well-structured consultation for polynucleotide treatment begins not with the treatment but with your skin. That means a detailed conversation about your concerns, your skin history, your previous treatments, and your expectations. It means a clinical examination of the skin, and ideally an objective assessment using technology such as VISIA skin analysis, which provides measurable data on skin texture, pore size, pigmentation, UV damage, and other parameters that inform treatment decisions.

Ultrasound assessment may also be relevant, particularly when injecting in areas where vascular anatomy needs to be understood, or where previous treatments have altered the tissue landscape. The assessment informs the recommendation, and the recommendation is explained clearly before any decision is made.

At Dr Alek Nikolic’s practice in Cape Town, the consultation process is structured around assessment before intervention. If polynucleotides are recommended, it is because the assessment supports that recommendation for your skin specifically, not because the treatment is currently in demand. If a different approach would serve you better, that will be the recommendation instead. The goal is an outcome that makes sense for your skin, your concerns, and your timeline, rather than a treatment that simply aligns with what is trending.

—

Frequently asked questions about polynucleotide injections

How many sessions of polynucleotide injections do you typically need to see a difference?

Most protocols involve an initial course of two to four sessions, spaced two to four weeks apart. Visible improvement typically begins after the second or third session, with the most noticeable changes emerging at three to six months as collagen remodelling progresses. Maintenance sessions are usually recommended every six to twelve months afterwards, though individual response varies.

Are polynucleotide injections safe, and what are the main risks?

When administered by a trained medical practitioner using appropriately purified formulations, polynucleotide injections have a generally favourable safety profile. The main risks include temporary redness, swelling, bruising, and tenderness at the injection sites. Allergic reactions are uncommon given the purification process, but are possible. Infection and nodule formation are rare but recognised risks with any injectable treatment. Choosing a practitioner with relevant training and a clear protocol for managing adverse events is the most important safety consideration.

Can polynucleotide injections replace dermal fillers or other injectables?

No, not as a like-for-like replacement. Polynucleotides and hyaluronic acid-based dermal fillers address different concerns through different mechanisms. Polynucleotides improve skin quality and stimulate regenerative processes. Dermal fillers restore volume and provide structural support. They can complement each other within a personalised protocol, but they are not interchangeable.

How do I know if my skin is a good candidate for polynucleotide injections?

Candidacy is determined by assessment rather than self-selection. Skin showing early to moderate quality decline, fine lines related to laxity, or reduced hydration and radiance may respond well. A detailed consultation and skin evaluation, ideally including objective diagnostic tools, will identify whether your concerns align with what polynucleotides can realistically address.

Do polynucleotide injections hurt, and is there any downtime?

Discomfort during polynucleotide injections is generally described as mild to moderate, similar to other superficial injectable treatments. Topical anaesthetic cream applied before the procedure reduces discomfort significantly for most people. Downtime is minimal: redness and mild swelling typically resolve within 24 to 48 hours, though some bruising may persist for a few days. Most people return to normal activities the same day or the following day.